Institution Directory

Clinical trials at Washington University School of Medicine

Sites in St. Louis, MO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1752

Shown on this page

Current sort

Live official records

Conditions: Alzheimer's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2031
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
Interventions: High-dose Methotrexate (8 gm/m2; HD-MTX); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • St Louis, Missouri • Winston-Salem, North Carolina

Conditions: Advanced Dedifferentiated Liposarcoma
Interventions: Abemaciclib, Placebo; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2034
U.S. locations: 184
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more

Conditions: AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 14
States / cities: San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 162
States / cities: Phoenix, Arizona • Irvine, California • Orange, California + 127 more

Conditions: Symptomatic Genetic Dilated Cardiomyopathy
Interventions: danicamtiv, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Interventions: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Interventions: Danicamtiv; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Large B-cell Lymphoma
Interventions: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™; Genetic · Drug · Device
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 63
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 51 more

Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Neratinib Maleate, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Lancaster, California + 13 more

Conditions: Advanced Pheochromocytoma and Paraganglioma, PCPG
Interventions: ONC206, ONC206: Dose 1, ONC206: Dose 2; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more

About this Washington University School of Medicine institution page

What this page lists: ClinicalTrials.gov records that list Washington University School of Medicine in St. Louis, MO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Washington University School of Medicine

Filter and sort this campus

Live official records

Dominantly Inherited Alzheimer Network (DIAN)

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

ALTERRA Post-Approval Study

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

About this Washington University School of Medicine institution page